PharmaCyte Biotech, Inc. (PMCB) stock
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$0.40+0.00 (+0.75%)
Close on Nov 12, 2026Market cap $4.32MP/E –Yield –
PharmaCyte Biotech EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
PharmaCyte Biotech's EPS for the twelve months ending Apr 30, 2026 was -$2.77. For fiscal 2026 it was -$2.77, down 186.8% from the year before. The highest annual figure on record is $3.19 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -$2.77 | -186.8% |
| FY2025 | Apr 30, 2025 | $3.19 | – |
| FY2024 | Apr 30, 2024 | -$1.80 | – |
| FY2023 | Apr 30, 2023 | -$0.22 | – |
| FY2022 | Apr 30, 2022 | -$0.27 | – |
| FY2021 | Apr 30, 2021 | -$2.45 | – |
| FY2020 | Apr 30, 2020 | -$4.23 | – |
| FY2019 | Apr 30, 2019 | $0.00 | – |
| FY2018 | Apr 30, 2018 | -$15.00 | – |
| FY2017 | Apr 30, 2017 | -$15.00 | – |
| FY2016 | Apr 30, 2016 | -$15.00 | – |
| FY2015 | Apr 30, 2015 | -$15.00 | – |
| FY2014 | Apr 30, 2014 | -$75.00 | – |
| FY2013 | Apr 30, 2013 | $0.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$0.54 | – |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$0.46 | -124.2% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -$0.17 | – |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | -$0.44 | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | -$0.39 | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $1.90 | – |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -$0.30 | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$0.65 | – |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -$0.26 | – |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -$0.54 | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$0.01 | – |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -$0.04 | – |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | -$0.09 | – |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -$0.07 | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | -$0.04 | – |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | -$0.06 | – |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -$0.64 | – |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$0.61 | – |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | -$0.49 | – |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | -$0.62 | – |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | -$0.79 | – |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $0.00 | – |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $0.00 | – |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | $0.00 | – |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $0.00 | – |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $0.00 | – |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $0.00 | – |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $0.00 | – |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $0.00 | – |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | $0.00 | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $0.00 | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $0.00 | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $0.00 | – |
| Q1 FY2017CQ2 2016 | Jul 31, 2016 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?